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Abstract: Gliomas remain one of the most challenging solid organ tumors to treat and 
are marked clinically by invariable recurrence despite multimodal intervention (surgery, 
  chemotherapy, radiation). This recurrence perhaps, is as a consequence of the failure to   eradicate 
a tumor cell subpopulation, termed cancer stem cells. Isolating, characterizing, and understand-
ing these tumor-initiating cells through cellular and molecular markers, along with genetic and 
epigenetic understanding will allow for selective targeting through therapeutic agents and holds 
promise for decreasing glioma recurrence.
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Introduction
Malignant gliomas are the most frequent cancers of the central nervous system and remain 
the most clinically challenging solid organ tumor.1 The median survival for   glioblastoma 
multiform patients has been a dismal 12 months, even with surgery,   radiation, and 
chemotherapy.2 With the recent use of the DNA alkylating agent   temozolomide, the 
median survival has increased by two months to approximately 14 months.3 This small 
yet significant increase in survival represents the greatest advancement in malignant 
glioma treatment over the last four decades. Recurrences occur almost exclusively in 
the brain, both at the site of initial tumor presentation and at distance, for example, the 
opposite hemisphere, illustrating the tumor’s infiltrative nature.
The cancer stem cell (CSC) hypothesis proposes that tumors contain a small   subset 
of cells with stem-like properties, which retain the exclusive ability to self-renew 
and sustain the growth of the tumor; essentially malignant cells that have stem cell 
like characteristics. Tumor stem cells were first identified in leukemia,4 and more 
recently also discovered in various solid tumors, including cancers of the brain such 
as glioblastomas, medulloblastomas and ependymomas.1 Brain CSCs, also known 
as brain tumor stem cells (BTSCs), are defined by (i) the capacity to self-renew, 
(ii) the ability to initiate brain tumors upon orthotopic implantation in xenografts 
and (iii)   multipotency, that is, the capacity to differentiate into cells with a neuronal, 
astrocytic or   oligodendroglial phenotype.5 In addition, BTSCs are characterized by 
the   expression of neural stem cell antigens and the ability to grow as nonadherent 
three dimensional aggregates termed neurospheres when cultured in the presence of 
epidermal growth factor (EGF) and   fibroblast growth factor (FGF) under   serum-free 
conditions. BTSCs possess many molecular and functional similarities with   normal 
neural stem cells (NSCs), supporting the hypothesis that brain tumors could arise Biologics: Targets and Therapy 2010:4 submit your manuscript | www.dovepress.com
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from neural stem or progenitor cells.6,7 Regardless of 
whether BTSCs arise from normal NSCs, it is known that 
once brain tumors develop these BTSCs evince properties 
fundamentally unique from the majority of malignant cells 
that comprise the bulk of the tumor. BTSCs are resistant to 
current radiotherapy and chemotherapy and as such are being 
investigated for their role in tumor recurrence.8,9
Glioma cellular heterogeneity
Light microscopic studies have shown that tumors that 
develop within normal tissues comprise a heterogeneous 
collection of cell types, frequently including immune cells, 
stromal cells (mesenchymal and endothelial cells), and a 
variety of normal or malignant cells specific to the tissue.10,11 
Further, cells within the tumor often seem to correspond to 
different stages of development. The prevailing explanation 
for tumor cell heterogeneity is a consequence of influences of 
the microenvironment and genomic instability that generate 
genetic and epigenetic changes.12 As a result, these factors 
prevent faithful and accurate replication and transmission of 
stable genotypes and phenotypes. Alternatively, an emerging 
concept poses that malignant cell populations may reflect the 
continuing operation of aberrant and malignant   differentiation 
processes creating heterogeneous tumor phenotypes derived 
from a small subset of CSCs.
BTSC cell of origin
In the nascent field of CSCs, many fundamental questions 
remain unanswered. One critical question is whether these 
cells arise from NSCs or from more differentiated cells 
that acquire the capacity of self-renewal. Evidence for 
the   latter exists in the hematopoietic field in blast crisis 
chronic myelogenous leukemia, in which a committed 
  granulocyte-macrophage progenitor may acquire   self-renewal 
capacity and thus ‘‘reacquire’’ stem-like properties due to 
the effects of later mutations.13 The term CSC is not meant 
to suggest a stem cell origin, but rather a cancerous cell that 
has stem cell-like properties, namely extensive self renewal 
and capacity for differentiation. However, which cells give 
rise to CSCs remains unknown.
isolation and characterization of BTSCs
Expanding on seminal work performed identifying CSCs 
in the hematopoietic system,14 CSCs in breast cancer were 
assayed and identified to provide the first evidence of CSCs 
in solid organ tumors.15 Subsequently, it was demonstrated 
that a subpopulation of cells from glioma could   recapitulate 
the primary glioma with xenograft transplantation of as 
few as 100 cells.5 Currently, CSCs can be best defined 
  experimentally by their ability to perpetuate tumors in serial 
transplantation xenotransplantation assays in vivo.13
An ideal in vitro BTSC assay would employ a highly 
  specific and quantitative guideline, only measuring the cells 
of interest. In addition, this assay should be sufficiently 
  sensitive so as to be able to measure candidate BTSCs 
when present at very low frequency. A few examples of 
in vitro assays   currently in use to enrich for CSCs include: 
sphere, serial   colony-forming unit (CFU) and label-retention 
(BrdU) assays.16 Another technique, the side population 
(SP)   phenotype (defined by its ability to efflux the nucleic 
acid-staining dye Hoechst) has been used to enrich for 
BTSCs.16–18
Flow sorting (fluorescence-activated cell sorting) 
techniques to prospectively isolate BTSCs on the basis of 
cell surface markers that   characterize and define bona fide 
CSCs would be ideal for cellular, molecular, and clinical 
investigation. Presently, the BTSC   subpopulation can be 
enriched for by sorting for the cell   surface marker CD133+ 
(Prominin-1).19,20 However, this marker is not an unequivocal 
marker that can be used for prospective   isolation of BTSCs 
in the brain. In fact, recent studies suggest that CD133− cells 
may also give rise to brain tumors.21,22
Recently, the contributions of the microenvironment have 
shown that BTSCs exist in a perivascular niche by   providing 
evidence that the microvasculature forms   scaffolding that 
may be necessary for maintaining or promoting the CSCs. 
Also, it has been shown that in the Patched mutant mouse 
(model of medulloblastoma), are not propagated by CD133+ 
cells but by cells expressing the progenitor markers Math1 
and CD15/SSEA-1.23 These cells have a distinct expression 
profile that suggests increased proliferative capacity and 
decreased   tendency to undergo apoptosis and differentiation. 
CD15 was also found in a subset of human medulloblasto-
mas, and tumors expressing genes similar to those found 
in murine CD15+ cells have a poorer prognosis. Therefore, 
CD15 may represent an important marker for CSCs in 
medulloblastoma.24,25 However, it clearly does not suffice 
to define CSCs solely on surface markers. To further under-
stand and characterize these aberrant stem cells, it would be 
prudent to link marker expression and self-renewal capacity 
with underlying molecular changes.
BTSCs as the source of glioma 
recurrence
Unlike other solid organ tumors, gliomas do not metastasize 
and patients succumb to this disease from invariable tumor Biologics: Targets and Therapy 2010:4 submit your manuscript | www.dovepress.com
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recurrence. This has been thought to result from insufficient 
reduction of tumor cell number, with most malignant cells 
considered competent for tumor formation.26
Glioma recurrence is now being understood to arise 
from a subset of tumor cells that exhibit stem cell-like 
  features, CSCs. Consequently, while current cancer 
  treatments are cytotoxic to the bulk of tumor cells, they 
fail to   eliminate CSCs, thereby making them the leading 
  candidates for the origin of glioma recurrence. To elucidate 
the biology of recurrent gliomas, we investigated the fraction 
of CSCs in primary vs recurrent (post treatment) gliomas. 
Human and mouse CSCs can be isolated by sorting for the 
cell surface marker CD133+. Although CD133 is not an 
  unequivocal marker useful for   prospective isolation, it is 
a highly   reliable marker of   malignant glioma CSCs with 
robust capacity to initiate tumors upon xenotransplanta-
tion and can be used to enrich for CSCs as a starting point 
for   investigation.21 Our   preliminary evidence using human 
CSCs in the   xenotransplantation assay shows that the CSC 
fraction (CD133+ cells) increases in recurrent gliomas 
(unpublished). Moreover, recent work by Bao et al and 
Piccirillo et al   provide new in vitro and in vivo evidence 
supporting the involvement of CSCs in tumors of the brain 
(Figure 1).20,27 Working with mouse models of glioblastoma, 
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Figure 1 Glioblastomas are heterogeneous tumors that contain a few tumor-initiating CD133+ stem cells among other, more differentiated, CD133− cells, including 
glioblastoma progenitor cells. A) Following radiation, the bulk glioblastoma responds and the tumor shrinks. But CD133+ cells activate checkpoint controls for DNA 
repair more strongly than CD133− cells, resist radiation and prompt the tumor to regrow. These cells could be targeted with DNA-checkpoint blockers to render them 
radiosensitive. B) BMPs normally cause NSCs to differentiate into astrocytes. when used to treat isolated glioblastoma CD133+ cells, they weaken the cells’ tumorigenicity 
both in vitro and when engrafted into mice, in vivo. The knowledge that a tumor retains a developmental hierarchy suggests that targeting different cell populations is a promising 
therapeutic strategy. Copyright © 2006, Nature Publishing Group. Reprinted with permission from Dirks PB. Cancer: stem cells and brain tumours. Nature. 2006;444 
(7120):687–688.
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the two groups described mechanisms by which BTSC cells 
escape antitumor treatment and approaches for forcing CSCs 
to mature to differentiated cells, with consequent loss of 
self renewal.
epigenetic instability in gliomas  
that create CSC competition  
and clonal diversity
Along with genetic and molecular mutations, epigenetic 
alterations also affect the expression of cancer genes and in 
gliomas multiple microRNAs are aberrantly expressed or 
repressed in both primary tumors and cell lines.28 Overall, 
microRNAs appear to play multiple roles in gliomas with 
respect to self renewal and clonal evolution of CSCs.12 
Moreover, in gliomas, hundreds of genes are subject to 
DNA hypermethylation at their CpG island promoters.29 
A subset of gliomas is also characterized by locus-specific 
and genome-wide decrease in DNA methylation, or DNA 
hypomethylation.28 Other epigenetic alterations, such as 
changes in the position of histone variants and changes in 
histone modifications are also likely to be important in the 
molecular pathology of gliomas. These epigenetic contribu-
tions must also be considered in the successful elucidation of 
BTSC biology and the possibility that in tumor recurrence 
BTSCs most likely compete with other BTSCs for domi-
nance in creating tumor recurrence. This possibility is one 
that would require molecular lineage techniques to follow 
the clonal evolution and diversity of BTSCs in primary vs 
recurrent gliomas.
Targeting elusive CSCs
Insights from other disciplines have led to unanticipated 
links between CSC biology, neurosciences, and epidemiol-
ogy. Mutations in neurotransmission pathways including 
sodium, potassium, and calcium channels have recently 
been shown to be a common occurrence in gliomas.30 These 
include mutations in all five of the major neurotransmission 
classes, serotonin, dopamine, acetylcholine, glutamate and 
GABA.26 Interestingly, this suggests that neuromodulatory 
mutations could confer selective advantage rather than just 
representing genetic alteration. Furthermore, unlike other 
mutations (ie, PTEN, P53) discovered in other cancers 
(ie, pancreases, breast, colon) mutations in neurotransmis-
sion pathways appear to be a feature unique to gliomas.31 
These mutually exclusive cancer driving mutations may thus 
be a consequence of the unique mechanism these pathways 
play in regulating CSCs and neural precursor pool size and 
tendency to differentiate.
Such perturbations in basal neurotransmission inputs 
from the surrounding NSC niche may be enough to change 
the dynamics of the CSCs and NSCs pool. This activation 
of normal lineage-specific signaling pathways in neural 
precursor derived cancer cells may provide a means of 
depleting the undifferentiated pool of cells that initiate and 
maintain brain tumor growth (Figure 2). For example, it has 
recently been demonstrated that pro-differentiating agents 
such as bone   morphogenic proteins (BMPs) can promote 
the differentiation of gliomas CSCs and prolong the life of 
mice xenotransplanted with human tumors. Moreover, in vivo 
neuromodulation of the metabotropic glutamate receptor 4 
(mGlu4), a candidate target for the treatment of Parkinson’s 
disease, has also been shown to attenuate medulloblastoma 
formation in mice. Similarly, mGlu2/3 antagonism also sup-
presses both the in vitro and in vivo growth of human glioma 
cells.30
The generality of this phenomenon is suggested by the 
finding that a broad spectrum of drugs that act on diverse 
  neurotransmission pathways inhibit both normal and 
  cancerous neural precursor cell proliferation in vitro. Based 
on a high through put screening of 1257 potential agents, the 
most potent NSCs and potentially anti-CSCs agents identified 
in these in vitro screens included the clinically prescribed 
dopamine agonist apomorphine and the   glutamate antagonist 
ifenprodil.32 Thus, chronic administration of   neuromodulatory 
agents may deplete CSCs pools in the neuropsychiatric patient 
and thereby protect against cancer initiation, perpetuation, or 
recurrence. This group of well tolerated neuropharmacological 
agents used in standard clinical practice may offer the prospect 
of rapid new clinical application following clinical trials in 
patients with brain cancer.
Conclusion
The immediate goal at hand should be a consensus 
identification of the elusive CSCs. This objective is achieved 
through the   integration and analysis of multiple methods 
including functional assays, marker analysis, and analysis 
of genetic and epigenetic signatures. Subsequently, this will 
allow for the isolation and characterization of these cells 
and a comparison to their normal stem cells counterparts. In 
understanding CSCs development and biology, we have the 
possibility of generating novel targets that could overcome 
issues of drug resistance, improve therapeutic efficacy, and 
decrease tumor recurrence.
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